📇 Rhumatologue · CAEN CEDEX 5 · (14) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
150.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
46
46 articles ont été cités au moins 46fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
10 323
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
388
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
113
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre François Baclesse
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Longitudinal evaluation of hippocampal subfields volumes and episodic memory in breast cancer patients and healthy controls
2026ArticleBrain imaging and behavior (Brain Imaging Behav)
Links between nocturnal hypoxia and cognitive function in breast cancer
2025ArticleScientific Reports
Screening and Risk Analysis of Atrial Fibrillation After Radiotherapy for Breast Cancer: Protocol for the Cross-Sectional Cohort Study “Watch Your Heart (WATCH)”
2025ArticleJMIR Research Protocols
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
2025ArticleLancet Oncology
Cognition and Return to Work Status 2 Years After Breast Cancer Diagnosis
2024ArticleJAMA Network Open
Trastuzumab deruxtecan in previously treated HER2 ‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France
2024ArticleCancer Medicine
Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study
2024ArticleCancer Research
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
2024ArticleEuropean Journal of Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CLCC F BACLESSE
3 AV DU GENERAL HARRIS BP 5026, 14076 CAEN CEDEX 5
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2024
Nature medicine · 2023
Abstract The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing ( n = 72, cohort 1), HER2-low ( n = 74, cohort 2) and HER2 non-expressing ( n = 40, cohort 3) metastatic breast cancer. In the full analysis set population ( n = 177), the confirmed objective response rate (primary endpoint) was 70.6% (95% confidence interval (CI) 58.3–81) in cohort 1, 37.5% (95% CI 26.4–49.7) in cohort 2 and 29.7% (95% CI 15.9–47) in cohort 3. The primary endpoint was met in cohorts 1 and 2. Secondary endpoints included safety. No new safety signals were observed. During treatment, HER2-expressing tumors ( n = 4) presented strong T-DXd staining. Conversely, HER2 immunohistochemistry 0 samples ( n = 3) presented no or very few T-DXd staining (Pearson correlation coefficient r = 0.75, P = 0.053). Among patients with HER2 immunohistochemistry 0 metastatic breast cancer, 5 of 14 (35.7%, 95% CI 12.8–64.9) with ERBB2 expression below the median presented a confirmed objective response as compared to 3 of 10 (30%, 95% CI 6.7–65.2) with ERBB2 expression above the median. Although HER2 expression is a determinant of T-DXd efficacy, our study suggests that additional mechanisms may also be involved. (ClinicalTrials.gov identifier NCT04132960 .)
The Lancet. Oncology · 2022
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Breast (Edinburgh, Scotland) · 2026 · Journal Article
Alexandre M, Teruel E, Dalenc F, de la Motte Rouge T, et al.
Cell reports. Medicine · 2026 · Journal Article
Cottu P, Kieffer Y, Lemonnier J, D'hondt V, et al.
European journal of cancer (Oxford, England : 1990) · 2026 · Journal Article
Bouteiller F, Gourgou S, Bringuier M, Galvin A, et al.
The New England journal of medicine · 2024 · Journal Article
Bardia A, Hu X, Dent R, Yonemori K, et al.
Cancer medicine · 2024 · Journal Article
Petit T, Hajjaji N, Antoine EC, Benderra MA, et al.
Cancer medicine · 2023 · Journal Article
Ruiz de Azua G, Kousignian I, Vaz-Luis I, Di Meglio A, et al.
Nature medicine · 2023 · Clinical Trial, Phase II
Mosele F, Deluche E, Lusque A, Le Bescond L, et al.
Breast cancer research and treatment · 2023 · Journal Article
Rassy E, Filleron T, Viansone A, Lacroix-Triki M, et al.
Annals of surgery · 2023 · Clinical Trial
Hotton J, Lusque A, Leufflen L, Campone M, et al.
Scientific reports · 2022 · Journal Article
Maliah A, Parikh R, Tayer-Shifman OE, Kimhi O, et al.
Breast (Edinburgh, Scotland) · 2022 · Journal Article
Vasseur A, Carton M, Guiu S, Augereau P, et al.
Cancers · 2022 · Journal Article
Rogé M, Salleron J, Kirova Y, Guigo M, et al.
Breast (Edinburgh, Scotland) · 2026 · Journal Article
Trédan O, Loirat D, Chabaud S, Toussaint P, et al.
The Lancet. Oncology · 2025 · Journal Article
Bonnefoi H, Lerebours F, Pulido M, Arnedos M, et al.
Breast cancer research and treatment · 2024 · Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Journal Article
Sandoval JL, Franzoi MA, di Meglio A, Ferreira AR, et al.
JAMA network open · 2023 · Multicenter Study
Kabirian R, Franzoi MA, Havas J, Coutant C, et al.
Hepatology (Baltimore, Md.) · 2025 · Journal Article
Bittermann T, Yagan L, Kathawate RG, Weinberg EM, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Journal Article
Grinda T, Antoine A, Jacot W, Cottu PH, et al.
BMC medicine · 2023 · Journal Article
Courtinard C, Gourgou S, Jacot W, Carton M, et al.
Frontiers in neuroscience · 2022 · Journal Article
Duivon M, Perrier J, Segura-Djezzar C, Joly F, et al.
Psycho-oncology · 2022 · Journal Article
Joly F, Pasquier D, Levy C, Mousseau M, et al.
Medicine and science in sports and exercise · 2022 · Journal Article
Briant A, Frandemiche C, Sevin E, Kaluzinski L, et al.
International journal of dermatology · 2026 · Journal Article
Gaumond SI, Mufarrej S, Angioli AM, Abdin R, et al.
JMIR research protocols · 2025 · Journal Article
Saint-Lary L, Pinel B, Panh L, Jimenez G, et al.
Additional file 2: of Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomics
Figure S2. Impact of voxels post-reconstruction resampling. Left panels display the mean decrease accuracy of textural features values and right panels display Spearman correlation matrixes of all PET metrics found to ha
sj-jpg-1-tam-10.1177_17588359211070362 – Supplemental material for Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
Supplemental material, sj-jpg-1-tam-10.1177_17588359211070362 for Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer by Amélie Mallet, Amélie Lusque, Chri
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
Abstract Background Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospectiv
sj-xlsx-2-tam-10.1177_1758835920987657 – Supplemental material for Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
Supplemental material, sj-xlsx-2-tam-10.1177_1758835920987657 for Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program by Marion Bertho, Julien Fr
sj-xlsx-4-tam-10.1177_1758835920987657 – Supplemental material for Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
Supplemental material, sj-xlsx-4-tam-10.1177_1758835920987657 for Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program by Marion Bertho, Julien Fr
sj-xlsx-6-tam-10.1177_1758835920987657 – Supplemental material for Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
Supplemental material, sj-xlsx-6-tam-10.1177_1758835920987657 for Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program by Marion Bertho, Julien Fr
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Ginzac A, Molnar I, Durando X, Motte Rouge T, et al.
JAMA oncology · 2023 · Journal Article
Huober J, Weder P, Ribi K, Thürlimann B, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Randomized Controlled Trial
Rugo HS, Im SA, Cardoso F, Cortes J, et al.
The Lancet. Oncology · 2022 · Randomized Controlled Trial
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, et al.
Psycho-oncology · 2022 · Journal Article
Joly F, Pasquier D, Levy C, Mousseau M, et al.
Journal of the National Cancer Institute · 2023 · Journal Article
Balazard F, Bertaut A, Bordet É, Mulard S, et al.
Cancer · 2023 · Journal Article
Licaj I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, et al.
Medicine and science in sports and exercise · 2022 · Journal Article
Briant A, Frandemiche C, Sevin E, Kaluzinski L, et al.
Psycho-oncology · 2022 · Journal Article
Joly F, Pasquier D, Levy C, Mousseau M, et al.
International journal of cancer · 2023 · Multicenter Study
Mailliez A, D'Hondt V, Lusque A, Caron O, et al.
Cancers · 2023 · Journal Article
François-Martin H, Lardy-Cléaud A, Pistilli B, Levy C, et al.